Paired GABA Ligand Formulation for Consistent Receptor Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing GABA receptor therapies often rely on single-agent formulations that are suboptimal due to reliance on endogenous GABA, leading to inconsistent efficacy, higher doses, and increased side effects, as orthosteric and non-orthosteric ligands are not co-formulated, limiting their synergistic potential.
Innovation Solution
A pharmaceutical composition that obligately pairs an orthosteric GABA receptor agonist with a non-orthosteric GABA receptor ligand, such as a positive allosteric modulator, ensuring concurrent availability and enhancing therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-agent GABA receptor formulations are used, then formulation simplicity is maintained, but therapeutic efficacy is inconsistent and higher doses are required
Solution Approach 1:
The patent combines orthosteric and non-orthosteric GABA receptor ligands into a single pharmaceutical composition. This merging of previously separate agents into one formulation ensures that both ligand types are delivered together, providing consistent therapeutic efficacy through synergistic interaction while maintaining formulation simplicity.
2Reliability
If higher doses of single-agent GABA formulations are administered, then therapeutic effect is achieved, but side effects increase
Solution Approach 1:
The patent changes the dosing parameters by administering lower individual doses of each ligand type in combination. The orthosteric ligand is given at a first effective dose and the non-orthosteric ligand at a second effective dose, where the combination produces therapeutic effects at lower total doses than single-agent therapy, thereby reducing side effects.
3Ease of operation
If non-orthosteric GABA receptor modulators are used alone, then ease of administration is maintained, but functional efficacy is limited without concurrent orthosteric ligand
Solution Approach 1:
The patent merges the non-orthosteric modulator with the orthosteric ligand in a single pharmaceutical composition. This ensures that when the formulation is administered, both ligands are delivered concurrently, enabling the non-orthosteric modulator to function effectively while maintaining ease of administration as a single agent.
4Reliability
If GABA is administered to cross the blood-brain barrier, then direct CNS therapeutic effect is achieved, but oral bioavailability is limited
Solution Approach 1:
The patent uses the non-orthosteric GABA receptor ligand as an intermediary that can enhance the effect of GABA or its agonists. Since the non-orthosteric ligand binds to a different site on the receptor, it can potentiate the therapeutic effect and improve oral bioavailability by amplifying the signal of the orthosteric ligand that does cross the blood-brain barrier.
Data Source
AI summary
A pharmaceutical composition is provided and includes at least one orthosteric GABA receptor ligand that directly binds to at least one GABA-A receptor or at least one GABA-B receptor at the endogenous GABA binding site, and at least one non-orthosteric GABA receptor ligand that binds a site distinct from the endogenous GABA binding site on at least one GABA receptor type. This ensures the orthosteric and non-orthosteric ligands for each receptor type are co-present. The orthosteric and non-orthosteric ligands may be co-formulated for concurrent availability, such that the presence of the orthosteric ligand enables or enhances the therapeutic effect of the non-orthosteric ligand.